|
|
|
Volumn 13, Issue 9, 2010, Pages 601-604
|
|
Asthma & COPD-IQPC's second conference
a
a
UCB PHARMA
(Belgium)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AIR 645;
AMG 317;
ANRUKINZUMAB;
ANTIASTHMATIC AGENT;
BENRALIZUMAB;
CHEMOKINE RECEPTOR CCR3 INHIBITOR;
CINQUIL;
DEXAMETHASONE;
EPI 2010;
ETANERCEPT;
GOLIMUMAB;
IMA 638;
INTERLEUKIN 13 ANTIBODY;
INTERLEUKIN 5 ANTIBODY;
INTERLEUKIN 9 ANTIBODY;
JN 7777120;
MEPOLIZUMAB;
OMALIZUMAB;
RESLIZUMAB;
RG 4930;
SIMPONI;
TPI ASM 8;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
UNCLASSIFIED DRUG;
MONOCLONAL ANTIBODY;
NEW DRUG;
ALLERGIC ASTHMA;
ASTHMA;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DRUG MECHANISM;
DRUG TARGETING;
HUMAN;
NONHUMAN;
ANIMAL;
DRUG DELIVERY SYSTEM;
DRUG DESIGN;
MOUSE;
PATHOPHYSIOLOGY;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
ANIMALS;
ANTI-ASTHMATIC AGENTS;
ANTIBODIES, MONOCLONAL;
ASTHMA;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
DRUGS, INVESTIGATIONAL;
HUMANS;
MICE;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
|
|
EID: 77956165677
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (9)
|
|
References (0)
|
